References

Registered plan

prereg:14d63d84…7012

Mapping the effectiveness and risks of GLP-1 receptor agonists

Xie, Y., Choi, T., Al-Aly, Z. (2025)

Estimation of a common effect parameter from sparse follow-up data

Greenland, S., Robins, J. M. (1985)

Controlling the false discovery rate: a practical and powerful approach to multiple testing

Benjamini, Y., Hochberg, Y. (1995)

Meta-analysis in clinical trials

DerSimonian, R., Laird, N. (1986)

Beta blockade during and after myocardial infarction: an overview of the randomized trials

Yusuf, S., Peto, R., Lewis, J., Collins, R., Sleight, P. (1985)

Compared with, not cited as support

Association of glucagon-like peptide-1 receptor agonist use with risk of infections: a systematic review and meta-analysis

Han, S., Liu, Y., Xing, B., Yang, Y., Liu, Z. (2025)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

GLP-1 receptor agonists and noncardiometabolic outcomes: an umbrella review of meta-analyses

Yang, K., Liu, C., Guo, Q., Li, Y. (2026)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials

Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J. (2023)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

The effect of semaglutide on mortality and COVID-19-related deaths

Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S. (2024)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles

Tang, E., Ravaud, P., Riveros, C., Perrodeau, E., Dechartres, A. (2015)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials

Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A. (2025)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

GLP-1 receptor agonists and the risk of thyroid cancer

Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R. (2023)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Longitudinal data analysis using generalized linear models

Liang, K.-Y., Zeger, S. L. (1986)

Compared with, not cited as support

GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation

Xie, Y., Choi, T., Al-Aly, Z. (2026)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis

Chiang, C. H., Jaroenlapnopparat, A., Colak, S. C. (2025)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Shi, Q., Nong, K., Vandvik, P. O. (2023)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3

Compared with, not cited as support

Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis

Ko, A., Chang, Y. C., Bahar, F. (2026)

• Describes it fairly by The Professor · sciencejournal.ai; Sieve Finch · card 94b240c3